Exabis Library
Welcome to the e-CCO Library!
DOP05: Single-cell RNAseq temporal analysis of ulcerative colitis patients undergoing tofacitinib treatment reveals a shift in myeloid cells towards pro-inflammatory phenotypes in refractory patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP05: Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP06 Non-invasive identification of adherent-invasive E. coli in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP060: Anti-TNF cord levels are significantly higher after IFX exposure during pregnancy compared with ADA exposure
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP060: Human amnion epithelial cells and their conditioned media reduces intestinal inflammation and fibrosis in a murine model of chronic colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP060: Real-world treatment pathway visualizations show low use of biologic therapies in Crohn's disease and ulcerative colitis in the United States
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP061: Human amnion epithelial cells reduce intestinal inflammation in a 2,4,6-trinitrobenzene sulfonic acid induced model of acute colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP061: Intrauterine exposure to thiopurine: assessing health outcome of children born to patients with an inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP061: Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP062: Malignancy and mortality in paediatric-onset inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP063: Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP063: Measurement of endoscopic severity in a Crohn’s disease multicentre paediatric inception cohort: poor correlation of SES-CD with Paediatric Crohn’s Disease Activity Index (PCDAI)
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP064: ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in inflammatory bowel disease patients with primary sclerosing cholangitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP065: Less anti-infliximab antibody formation in paediatric Crohn’s patients on concomitant immunomodulators
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP065: Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM